(COLUMBUS, Ohio) – Andelyn Biosciences announces the promotion and appointment of Cyrill Kellerhals as Chief Operations Officer (COO). Cyrill will lead Andelyn’s cGMP Manufacturing and Operations activities to ensure the continuation and enhancement of quality programs and products at the cell and gene therapy manufacturing company. He will assume the role of COO on Monday, March 4th, 2024.

“We are incredibly fortunate to have this caliber of talent within our existing leadership team at Andelyn to promote to this level. Cyrill exemplifies Andelyn’s culture, has 20+ years of industry-related experience, demonstrates transformational leadership at its best, and has key institutional knowledge to continue to propel us forward in serving our purposeful mission. Not only does Cyrill possess the hard skills required to be successful in this role, but also embodies our core values and displays a level of passion and respect for the work that we do to enable us to continue Pioneering Solutions that Turn Hope into Reality™ for our clients and patients we serve. We know Cyrill will add immense value to this role, and we look forward to his transition into this executive position.” said Wade Macedone, Chief Executive Officer of Andelyn Biosciences.

“It is a great honor to step into the COO role at Andelyn and I look forward to the opportunity of leading our Operations organization to pursue our mission of changing patient lives,” said Cyrill.

Cyrill is an experienced leader in the Pharmaceutical, Biopharmaceutical, Cell & Gene Therapy, and Medical Device industries. He has an impressive background in Manufacturing, R&D, and Quality, with over 20 years of leadership across the Asia, Europe, and North America markets. His expertise lies in leading complex manufacturing organizations, managing large-scale projects, and controlling expansive operational budgets to ensure on-time and within-budget delivery of products.

Prior to his promotion as COO, Cyrill served as Andelyn’s Head of Manufacturing for three years. During his tenure he oversaw the construction and commissioning of the Andelyn Corporate Center (ACC), an impressive 185,000 sq. ft cGMP state-of-the-art manufacturing facility, drove operational set-up of the site, and achieved the successful start-up of GMP AAV production, ensuring targets and deadlines were met for clients. Prior to joining Andelyn, Cyrill held various leadership and executive positions within Quality and Operations at Novartis and CSL Behring. He holds a Bachelor’s Degree in Chemical Engineering from the University of Basel in Switzerland and a Master of Business Administration specializing in Business Analytics from Syracuse University.